Less than a tenth of people who could benefit from GLP-1 drugs such as Wegovy can access them, caution the global health agency as it releases its first recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for increased and just availability to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidelines affirms that excess weight is a lifelong illness that can be managed with holistic and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are major barriers to widespread availability to the treatments that can assist patients in reducing considerable body mass, explains the organization.
GLP-1 Therapy Supply Crisis
Even under the present most optimistic outlook, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – under 10% of those who need them, per the health organization.
The advice encourages governments and firms to increase access, by approaches such as patent sharing.
A patent on a key compound – the core ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
How Obesity Drugs Function
These medications mimick a natural hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so individuals reduce food intake.
Individuals usually see weight reduction in the initial weeks of starting on the regular doses.
Research indicates users may see weight return after a year of halting the drug, when their usual food cravings resume.
To be above a healthy weight raises your chance for contracting health problems, including diabetes, heart disease, stroke, and certain malignancies.
Excess weight affects individuals in all nations and was linked to millions of deaths worldwide in 2024, as per the health agency.
